Two people out of every 1,000 will suffer from Parkinson’s Disease which equates to about 127,000 people in the UK & over 4 million people globally.
Many Parkinson’s disease patients experience unpleasant side effects, such as involuntary movements called ‘dyskinesia’, as a result of levodopa medication.
Levodopa-induced dyskinesia (LID) can be improved by adjusting medication dosage to find a tolerable balance between the benefits and side effects.
LID-Monitor offers a safe, simple and unobtrusive way of monitoring dyskinesia in a patient’s own home and allows specialists to measure the effectiveness of the medicine prescribed to a patient for their condition.
Six small wireless sensors are worn by a patient with known Parkinson’s around the home over periods of up to 24 hours.
Movements associated with dyskinesia and the symptoms of Parkinson’s disease are recognised by the system and transmitted electronically to specialists in an easy to interpret graphical format.
What is Parkinson's disease?
Parkinson’s is a progressive neurological condition caused by a lack of a chemical called dopamine. Dopamine allows messages to be sent to the parts of the brain that co-ordinate movement. Parkinson’s destroys nerve cells that produce the brain chemical dopamine.
What is dyskinesia?
Dyskinesia refers to involuntary muscle movements, including twitches, jerks and restlessness, which can affect various parts of the body, such as the arms, legs and upper half of the body.
What is Levodopa‐induced dyskinesia?
Levodopa is one of the main drugs used to treat Parkinson’s symptoms. Many patients develop problems with dyskinesia as a result of taking it, known as Levodopa-induced dyskinesia (LID). It can fluctuate in severity throughout the day but may be reduced by altering medication regimen times and dosages.
People in the UK with Parkinson's
Millions of pounds, the LID-Monitor could save the NHS
Of all diagnoses of neurodegenerative conditions are unsound
Hours sensors can be worn at home
Benefits of the LID-Monitor
Cost of treatment in UK each year was estimated to be £1.5 billion in 2013 and over $25 billion in USA. As the disease progresses the likelihood of emergency admission becomes greater. The York Health Economics Consortium has estimated that the LID-Monitor could potentially save the NHS of up to £84 million per year in reduced consultations and hospital admissions.
Non-invasive, safe and quick to use
- Up to six sensors measuring symptoms in all limbs
- Automatic uploading of data
- No need to undertake specific clinical tasks
- No reliance on internet connection
- Tailored to the clinical need
- Patient can be monitored in their own home without the need to travel to hospital